What Cyber Security Concerns Should Employers Have?

 

We’re living in an increasingly digital world, which is why cybersecurity is more important than ever. Brands in particular have adapted to a more digital way of doing business and while there are many benefits of using technology to run a company, legal issues may arise surrounding cyber specific topics.

Guy Sereff, Senior Counsel at Michael Best & Friedrich LLP, is a privacy and cybersecurity attorney who primarily focuses on helping clients with a wide range of cyber security related issues, such as governance issues, policies, and compliance, as well as “all of the fun questions that come up around data from a legal perspective and also from a practical perspective. I’ve got quite a bit of history within enterprises,” Sereff explained.

Sereff warns that as COVID-19 forced countless office workers to work in their homes, that new issues relating to digital privacy and security are arising, “I think the big issues that are popping up and are going to continue to pop up, is how consistent was the deployment of the work from home strategy?” Sereff posed a series of questions that can serve as a starting off point for companies concerned about their remote workforce’s security levels, “How consistently were your employees using whatever environment you created? Because the issue that I see is going to arise, as we return to work, is how much work product was generated on a PC that wasn’t connected to a VPN or a VDI?”

Depending on what resources employees are using from home, security and compliance issues may be a concern. For example, employers may not know the answers to these questions which may be cause for concern.

  • How many file shares were used?
  • Were employees utilizing Dropbox?
  • Were they utilizing Google Cloud?

“The resulting issue is, how much proliferation of data are we going to see? And I think that’s one of the big things to try to get a grip on now, is getting control of any of that data that may have leaked outside,” Sereff said.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

 

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More